Phase 3 Trial

Novartis' Lung Cancer Candidate Misses Primary Goal In Post Surgery Setting
BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial

Phase 3 Trial Recent News

Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer
Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC).
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
Eli Lilly And Co (NYSE: LLY) 
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
Veru Inc (NASDAQ: VERU) has 
Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has 
Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
Theravance Biopharma Inc (NASDAQ: TBPH) 
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
Argenx SE (NASDAQ: ARGX) announced 
Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data
Merck - Ridgeback's COVID-19 Antiviral Shows Rapid Elimination Of Infectious SARS-CoV-2 Than Placebo
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics will present data evaluating Lagevrio (molnupiravir), an oral COVID-19 antiviral, at the 2022 European Congress of Clinical Microbiology & Infectious Diseases.
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC) 
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY) 
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
Roivant Sciences Ltd's (NASDAQ: ROIV) subsidiary Dermavant Sciences announced results from Phase 3 PSOARING 3 long-term extension study of tapinarof cream 1% for plaque psoriasis in adults.
Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study
ObsEva Unveils Additional Efficacy Results for Linzagolix In Endometriosis-Associated Pain
Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets)